5 billion for the fourth quarter of 2017 compared to $3
3 billion of its new hepatitis C drug Sovaldi in 2014, a figure that brought it close to being the best-selling drug in the world in only its first year
Having achieved the biggest drug launch to date by generating an astonishing $2
Thanks to pent-up demand for improved hep C treatment options, Gilead reaped $5
Dive Brief: After being winning FDA approval on October 10, 2014, Gilead's Harvoni (ledispavir / sofosbuvir) racked up $2
Gilead’s recent financial statements show U
Original Data: Centers for Medicare & Medicaid Services
Sovaldi broke all records for a new pharmaceutical launch when it reached the market - racking up $10bn in sales in 2014 (its first full year on the market)
mssle
China’s auto sales are expected to decline this month due to disruption from the Lunar New Year holiday and customers holding out for more price cuts
1:55
Listen
27 billion, or more than 45%, of revenues alone while analysts anticipated that the drug would yield just $1
In PBM-Owned Specialty Pharmacies' Financial Win From Sovaldi, I highlighted Leerink analyst David Larsen’s estimates that CVS Caremark and Express Scripts gained as much as $600 million in revenues from Sovaldi first quarter sales
(/ ˈ ɡ ɪ l i ə d /) is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir
As for the Sovaldi China expansion, the main risk is whether the actual sales figure will be as robust as the data suggested
4 percent, though all of its growth came from Japan and other international markets
Identify the key sales metrics you need, such as win rate and average deal size
Sales growth is a dynamic indicator of your business’s health and market position
36bn by 2018, according to consensus forecasts from EvaluatePharma
I would expect the Cosmos data on Sovaldi/Olysio at the EASL meeting to be favorable, but Sovaldi cures the liver-wasting disease in 9 of 10 patients, but treatment can cost more than $90,000
Drug maker Gilead Sciences, Inc
Total prescriptions (TRx) for Sovaldi rose almost 70% to 1,764 for the The report covers the Global Market Assessment of the Sovaldi covering the historical global sales and also provides the Sovaldi sales estimation during the forecasted period (2019-2021)
, where 65% of its usage is in patients with HCV genotype 1